ENTPD1 and neoplasm: SRF617, a fully human anti-CD39 antibody, has been shown to reduce ATPase activity and CD39 expression while simultaneously enhancing CD8+ T cell infiltration within the TME, ultimately leading to tumor growth inhibition [239].